

**FOR IMMEDIATE RELEASE****CleopatraRX inventor, Dr. Rhonda Voskuhl, Profiled in Lancet Neurology**

**Los Angeles, California (January 22, 2024)** – CleopatraRX™, a nutraceutical company offering the prescription treatment PearPAK™ for the prevention of cognitive decline during menopause, is proud to announce Dr. Rhonda Voskuhl's profile publication in Lancet Neurology, the #1 ranked neurology journal in the world. Each month, Lancet Neurology selects one person worldwide to profile; the February 2024 issue is Dr. Voskuhl, inventor of PearPAK™ by CleopatraRX. This recognition signifies her impact on neurology research and clinical application. The profile features her innovation studies on the effect of sex hormones and sex chromosomes in neurological disorders, including multiple sclerosis and age-related cognitive decline.

Additionally, Dr. Voskuhl, the Director of the Multiple Sclerosis Program at the University of California, Los Angeles (UCLA) and the neurologist for the UCLA Comprehensive Menopause Care Program, has been honored with the Rachel Horne Prize for Women's Research in Multiple Sclerosis. This award, received in October 2023, highlights her contributions to understanding the impact of loss of estrogen during menopause on neurodegeneration.

Dr. Voskuhl's bedside-to-bench-to-bedside approach, matching clinical observations with laboratory insights, has led to several clinical trials. This approach underscores her commitment to transforming scientific discoveries into new treatments for patients, changing our understanding of neurodegenerative diseases. *"Life is too short to spend decades studying something in the lab that ends up not relevant to people's suffering,"* she states.

The publication of Dr. Voskuhl's profile in such a prestigious journal is a personal achievement and a testament to the importance of her work in neurology, reflecting its global impact.

We celebrate Dr. Voskuhl's story, one of innovation and perseverance. We honor her invaluable contributions to neurology and her continued pursuit of knowledge to improve patients' lives.

Read full published article: [https://www.thelancet.com/journals/laneur/article/PIIS1474-4422\(24\)00002-4/fulltext](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00002-4/fulltext)

For more information, please contact:

Jaci Volles, Chief Marketing Officer

CleopatraRX

Email: [j.volles@cleopatrarx.com](mailto:j.volles@cleopatrarx.com)

---

**About Dr. Rhonda Voskuhl:** Professor of Neurology at UCLA, Dr. Voskuhl holds the Jack Skirball Chair, is Director of the UCLA MS program, faculty at the UCLA Brain Research Institute, and serves as a neurologist for the UCLA Comprehensive Menopause Care program. With over 200 publications, including work in prestigious journals like Nature and Lancet Neurology, she conducts pre-clinical and clinical research to find treatments to prevent neurodegeneration. Her work on estrogen loss and cognition during menopause originated from extensive research on cognitive function in women with multiple sclerosis.

**About CleopatraRX:** CleopatraRX™ is a nutraceutical company founded on Dr. Rhonda Voskuhl's innovative work, creating the PearPAK™ treatment, a prescription for the prevention of cognitive decline during menopause. CleopatraRX holds exclusive licenses for numerous UCLA patents in the U.S. and Europe for treatments to improve cognition in neurodegenerative conditions.

**About The Lancet:** The Lancet is one of the world's oldest and most respected peer-reviewed general medical journals. Founded in 1823, The Lancet stands as the highest-impact academic journal globally, renowned for publishing original research, review articles, and more in various medical fields, with Lancet Neurology focused on the field of neurology.